912259-10-0

Basic information

• Product Name: 6,7-dihydro-1H-indazol-4(5H)-one
• Synonyms: 6,7-dihydro-1H-indazol-4(5H)-one;2,5,6,7-Tetrahydro-4H-indazol-4-one;6,7-dihydro-2H-indazol-4(5H)-one
• CAS NO: 912259-10-0
• Molecular Formula: C₇H₈N₂O
• Molecular Weight: 136.15122
• Mol File: 912259-10-0.mol

Chemical Properties

• Melting Point: 229-231℃
• Appearance: /
• Density: 1.305±0.06 g/cm3 (20 ºC 760 Torr)
• CAS DataBase Reference: 6,7-dihydro-1H-indazol-4(5H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-dihydro-1H-indazol-4(5H)-one(912259-10-0)
• EPA Substance Registry System: 6,7-dihydro-1H-indazol-4(5H)-one(912259-10-0)

Safety Data

• Hazardous Substances Data: 912259-10-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6,7-dihydro-1H-indazol-4(5H)-one is used as a pharmaceutical agent for its antitumor properties, targeting the inhibition of cancer cell growth. Its potential use in the treatment of cancer is supported by studies that highlight its ability to interfere with the proliferation of cancer cells, offering a new avenue for cancer therapy.
Used in Anti-inflammatory Applications:
6,7-dihydro-1H-indazol-4(5H)-one is utilized as an anti-inflammatory agent, leveraging its capacity to reduce inflammation, which is a common characteristic of various diseases and conditions. This application can be beneficial in managing inflammatory responses and associated pain.
Used in Analgesic Applications:
As an analgesic agent, 6,7-dihydro-1H-indazol-4(5H)-one is employed to alleviate pain. Its structure and activity suggest that it could be a potential candidate for the development of new pain management therapies, providing an alternative to existing analgesics.

Upstream product

• 85302-07-4 2-(dimethylaminomethylene)cyclohexane-1,3-dione 
• 5815-08-7 tert-Butoxybis(dimethylamino)methane 
• 504-02-9 1,3-cylohexanedione 
• 64-18-6 formic acid 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 1355248-96-2 C₁₅H₁₅BrN₂O₂ 
• 955406-75-4 tert-butyl 4-oxo-4,5,6,7-tetrahydro-1H-indazole-1-carboxylate 
• 955406-76-5 4-oxo-4,5,6,7-tetrahydro-indazole-2-carboxylic acid tert-butyl ester 
• 1314139-86-0 5-bromo-2-trityl-2,5,6,7-tetrahydro-indazol-4-one 
• 1314139-87-1 5-bromo-2-(4-methoxy-benzyl)-2,5,6,7-tetrahydro-indazol-4-one 
• 1314140-30-1 2-(4-methoxy-benzyl)-2,5,6,7-tetrahydro-indazol-4-one 
• 1027617-67-9 2-methyl-4,5,6,7-tetrahydro-2H-indazol-4-one 
• 586353-04-0 2-triphenylmethyl-6,7-dihydro-2H-indazole-4(5H)-one 
• 1416247-34-1 4-(6,7-Dihydro-1H-indazol-4-yl)-2-fluoro-benzonitrile 
• 1416245-63-0 4-(6,7-dihydro-2H-indazol-4-yl)benzonitrile 
• 1235325-58-2 1-tosyl-6,7-dihydro-1H-indazol-4(5H)-one 
• 1416247-44-3 2-(p-tolylsulfonyl)-6,7-dihydro-5H-indazol-4-one 
• 1416245-40-3 4-[4-hydroxy-1-(p-tolylsulfonyl)-6,7-dihydro-5H-indazol-4-yl]benzonitrile 
• 1416245-42-5 4-[4-hydroxy-2-(p-tolylsulfonyl)-6,7-dihydro-5H-indazol-4-yl]benzonitrile 

Relevant articles and documents

Design, synthesis and biological evaluation of selective histone deacetylase 6 (HDAC6) inhibitors bearing benzoindazole or pyrazoloindazole scaffold as surface recognition motif

A series of compounds were designed and synthesized based on the compound 11i bearing phenylpyrazole scaffold with histone deacetylase 6 (HDAC6) inhibitory activity. Most of the compounds showed considerable inhibitory activity against HDAC6 and compound

1,5,6,7-Tetrahydro-4H-indazol-4-ones as human neutrophil elastase (HNE) inhibitors

Human neutrophil elastase (HNE) is a serine protease that is expressed in polymorphonuclear neutrophils. It has been recognized as an important therapeutic target for treating inflammatory diseases, especially related to the respiratory system, but also f

Mercaptan compound having HDAC6 (histone deacetylase 6) inhibitory activity and application thereof

The invention belongs to the technical field of medicines and relates to a mercaptan compound having an anti-tumor activity, in particular to a mercaptan compound containing a 6(7)-substituted-N-(6-decylhexyl)-pyrazolo[3,4-e] indazole-3-formamide fragment

Hydroxamic acid compound having HDAC6 inhibitory activity and application thereof

The invention belongs to the technical field of medicines, and relates to hydroxamic acid compound having HDAC6 inhibitory activity and antitumor activity, in particular to a hydroxamic acid compoundwith benzoindazole and pyrazolindazole as mother nucleus

AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES

2-Acylindazole compounds of formula I or formula II are disclosed. These compounds inhibit Coagulation Factor XIIa. They are useful to treat autoimmune diseases.

Pyrazolo[3,4-h]quinolines promising photosensitizing agents in the treatment of cancer

A new series of pyrazolo[3,4-h]quinolines, heteroanalogues of angelicin was conveniently prepared with a broad substitution pattern. A large number of derivatives was obtained and the cellular photocytotoxicity was evaluated in vitro against 5 different h

Novel crown ether functionalized imidazolium-based acidic ionic liquid catalyzed synthesis of pyrazole derivatives under solvent-free conditions

Abstract An innovatively designed novel crown ether functionalized imidazolium-based reusable acidic ionic liquid [crown ether MIm] [HSO4] has been efficiently implemented for the synthesis of pyrazole derivatives using various substituted enaminones, hydrazine hydrate and phenyl hydrazine under solvent-free conditions. Structural novelty and task efficiency of the catalyst, high yields of desired products, greener approach attributing high atom economy and solvent-free conditions render this protocol suitable to cope with the current demand in contemporary organic chemistry. The inventive idea of utilizing crown ether functionalized ionic liquid as a catalyst was for the first time demonstrated in this protocol.

TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention describes and claims compounds of the Structural Formula (I), Structural Formula (II), or Structural Formula (III). In Formula (I), R1, R2, R3 and R3' are -H or methyl, or R3 and R3' taken together form a double bond, or R3' is -H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is -H or -F, and R5 is -H, methyl, -Cl or -Br. In Formula (II), R1 is -H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is -H or -F, and "Y" is: (a) -CH2-; (b) -CR6H-O-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (c) -CR6H-N(R9)-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (d) -CH2-C(R9)(R10)-C(R7)(R8)-, wherein R7, R8, R9 and R10 are independently -H or -methyl, or both R7 and R8 are -F, R9 and R10 are independently -H or -methyl, or both R9 and R10 are -F, or R9 and R10 taken together are (O=), which together with the carbon to which they are attached forms a carbonyl group.

TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention describes and claims compounds of the Structural Formula I, Structural Formula II, or Structural Formula III: wherein R1, R2, R3 and R3' are -H or methyl, or R3 and R3 taken together form a double bond, or R3' is -H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is -H or -F, and R5 is -H, methyl, -CI or -Br, Formula II wherein R1 is -H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is -H or -F, and "Y" is: (a) -CH2-; (b) -CR6H-0-CR7R8-, wherein R6, R7, and R8 are independently - H or methyl; (c) -CR6H-N(R9)-CR7R8-, wherein R6, R7, and R8 are independently -H or methyl; (d) -CH2-C(R9)(R10)-C(R7)(R8)-, wherein R7, R8, R9 and R10 are independently - H or -methyl, or both R7 and R8 are -F, R9 and R10 are independently -H or -methyl, or both R9 and R10 are -F, or R9 and R10 taken together are (0=), which together with the carbon to which they are attached forms a carbonyl group.

Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators

There is an increasing amount of evidence to support that activation of the metabotropic glutamate receptor 4 (mGlu4 receptor), either with an orthosteric agonist or a positive allosteric modulator (PAM), provides impactful interventions in diseases such as Parkinson's disease, anxiety, and pain. mGlu4 PAMs may have several advantages over mGlu4 agonists for a number of reasons. As part of our efforts in identifying therapeutics for central nervous system (CNS) diseases such as Parkinson's disease, we have been focusing on metabotropic glutamate receptors. Herein we report our studies with a series of tricyclic thiazolopyrazoles as mGlu4 PAMs.